---
title: "CCCC.US (CCCC.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CCCC.US/news.md"
symbol: "CCCC.US"
name: "CCCC.US"
parent: "https://longbridge.com/en/quote/CCCC.US.md"
datetime: "2026-05-20T08:56:37.618Z"
locales:
  - [en](https://longbridge.com/en/quote/CCCC.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CCCC.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CCCC.US/news.md)
---

# CCCC.US (CCCC.US) — Related News

### [C4 Therapeutics Realigns Finance Leadership After Officer Departure](https://longbridge.com/en/news/286617295.md)
*2026-05-15T21:12:37.000Z*
> C4 Therapeutics announced the departure of Chief Accounting Officer Mark Mossler, effective May 15, 2026, with no report

### [Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday](https://longbridge.com/en/news/286288549.md)
*2026-05-13T15:31:33.000Z*
> On Wednesday, several stocks saw significant gains, led by Vishay Intertechnology (VSH), which rose 10% after reporting 

### [Earnings Scheduled For May 12, 2026](https://longbridge.com/en/news/286090966.md)
*2026-05-12T11:11:43.000Z*
> On May 12, 2026, several companies are scheduled to report their earnings. Notable projections include Sionna Therapeuti

### [C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://longbridge.com/en/news/286088253.md)
*2026-05-12T11:01:39.000Z*
> On May 12, 2026, in Watertown, Massachusetts, C4 Therapeutics, Inc. (C4T) disclosed its financial performance for the fi

### [Jefferies Remains a Buy on C4 Therapeutics (CCCC)](https://longbridge.com/en/news/282349247.md)
*2026-04-10T12:56:46.000Z*
> In a report released today, from Jefferies maintained a Buy rating on C4 Therapeutics, with a price target of $14.00.Eas

### [Roche and C4 Therapeutics to advance degrader-antibody conjugates research](https://longbridge.com/en/news/282332145.md)
*2026-04-10T09:19:10.000Z*
> Roche has entered a collaboration with C4 Therapeutics to advance research on degrader-antibody conjugates (DACs) for ca

### [Should Roche’s Bet on Degrader-Antibody Conjugates and New HIV/Hepatitis Test Reshape Roche (SWX:ROP)?](https://longbridge.com/en/news/282274004.md)
*2026-04-10T01:57:28.000Z*
> Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates for oncology and launched the cobas MPX